Skip to content

Impact of Pharmacist in Cardiology Service

Presence of a Clinical Pharmacist in a Cardiology Department: What Impact on the Management of Diabetic Patients Within Care Pathways? Example of Inpatient Cardiac Patients at GHPSJ

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03206294
Enrollment
44
Registered
2017-07-02
Start date
2017-03-08
Completion date
2018-12-31
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathy, Diabetic

Brief summary

The coverage of the diabetes is a multidisciplinary care, with practitioners' implication(hospital and liberal), and other medical and paramedical profession: doctor, pharmacist, male nurse, nutritionist, etc. In fact there is a real importance of link between hospital and general medecine outside. That's why the pharmacist's presence during the hospitalization seems to be a good alternative to make the link between hospital and the outside pharmacist where patient take his treatment. Hospital pharmacis proceed to a treatment conciliation at the entrance and at discharge. By this conciliation the aim of the study is to show and quantify the impact of pharmacist presence on therapeutic target .

Interventions

OTHERpharmacist assessment

St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization

Sponsors

Fondation Hôpital Saint-Joseph
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diabetes type 2 patient hospitalized in cardiology service * Hospitalization more than 24 hours * with insuline or/and oral anti diabetic

Exclusion criteria

* diabètes type 1 * iatrogenic hyperglycaemia * hospitalization for cardia angiography

Design outcomes

Primary

MeasureTime frame
Measurement of biological test glycosylated haemoglobin evolution between the entrance and discharge5 days

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026